Accent Therapeutics, Inc.

Brian Andrew Sparling

Kenneth William Duncan

Andrew Stewart Tasker

Matthew H Daniels

Gavin Whitlock

Mary-Margaret Zablocki

Provided are compounds of the Formula (IIIA): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of KIF18A and in the treatment of a variety of KIF18A mediated conditions or diseases, such as cancer.

Inhibitors of KIF18A and uses thereof

Provided are compounds of the Formula (IVB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.

Inhibitors of RNA helicase DHX9 and uses thereof

Provided are compounds of the Formula (IIB): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.

Growing community of inventors

Saugus, MA, United States of America

Brian Andrew Sparling